Literature DB >> 10850398

Diurnal changes in the pharmacokinetic behavior of amikacin.

N Bleyzac1, B Allard-Latour, A Laffont, J Mouret, R Jelliffe, P Maire.   

Abstract

This retrospective study evaluated possible differences in the pharmacokinetic behavior of amikacin between the morning (AM) and evening (PM). Of 634 patients receiving amikacin therapy, 17 received a dose every 12 hours (an i.v. infusion at 8:00 AM and 8:00 PM) with amikacin serum levels obtained after both the AM and PM infusions. Pharmacokinetic parameter values were estimated by the nonparametric EM algorithm (USC*PACK clinical software) for a one-compartment model. All patient data were analyzed in three ways. The parameter values were estimated by fitting the model first only to the serum levels drawn following the AM dose; second, only to the data following the PM dose; and third, to all serum levels (AM + PM). Parameter values found were (mean, median, SD respectively): AM: Kel = 0.181114 h(-1), 0.224460 h(-1), 0.058820 h(-1); Vol = 23.657507 L; 23.376231 L; 1.353253 L; Cl = 4.326720 L x h(-1), 5.303726 L x h(-1), 1.447731 L x h(-1); PM: Kel = 0.110151 h(-1); 0.121295 h(-1); 0.016860 h(-1); Vol = 28.948043 L; 24.091703 L; 9.266628 L; Cl = 3.081761 L x h(-1), 2.810615 L x h(-1); 0.705874 L x h(-1); AM + PM: Kel = 0.165321 h(-1); 0.131796 h(-1); 0.075425 h(-1); Vol = 25.479043 L; 26.187970 L; 5.367054 L. These findings are in agreement with the known diurnal rhythm of glomerular filtration rate. Because pharmacokinetic parameter values are most often estimated using AM data, this may lead to an overevaluation of these values compared with PM or to values for the entire day. The resulting drug regimens may therefore be overestimated regarding the elimination rate constant and underestimated regarding the volume of distribution.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10850398     DOI: 10.1097/00007691-200006000-00012

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  10 in total

Review 1.  Review: therapeutic drug monitoring in pediatrics.

Authors:  Offie Porat Soldin; Steven J Soldin
Journal:  Ther Drug Monit       Date:  2002-02       Impact factor: 3.681

Review 2.  The influence of cardiovascular physiology on dose/pharmacokinetic and pharmacokinetic/pharmacodynamic relationships.

Authors:  Pietro Fagiolino; Rosa Eiraldi; Marta Vázquez
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

3.  Appropriateness of timing of drug administration in electronic prescriptions.

Authors:  Arwa Hassan; Walter E Haefeli
Journal:  Pharm World Sci       Date:  2010-01-10

Review 4.  Circadian rhythms in gene expression: Relationship to physiology, disease, drug disposition and drug action.

Authors:  Siddharth Sukumaran; Richard R Almon; Debra C DuBois; William J Jusko
Journal:  Adv Drug Deliv Rev       Date:  2010-06-11       Impact factor: 15.470

5.  Diurnal variation in the biliary excretion of flomoxef in patients with percutaneous transhepatic biliary drainage.

Authors:  S Hishikawa; E Kobayashi; K Sugimoto ; M Miyata; A Fujimura
Journal:  Br J Clin Pharmacol       Date:  2001-07       Impact factor: 4.335

6.  Identifying 24 h variation in the pharmacokinetics of levofloxacin: a population pharmacokinetic approach.

Authors:  Laura Kervezee; Jasper Stevens; Willem Birkhoff; Ingrid M C Kamerling; Theo de Boer; Melloney Dröge; Johanna H Meijer; Jacobus Burggraaf
Journal:  Br J Clin Pharmacol       Date:  2015-11-25       Impact factor: 4.335

7.  Chronopharmacokinetics of once daily dosed aminoglycosides in hospitalized infectious patients.

Authors:  Erik van Maarseveen; Wai Hong Man; Johannes Proost; Cees Neef; Daniël Touw
Journal:  Int J Clin Pharm       Date:  2015-01-24

8.  Daily variations in ceftriaxone pharmacokinetics in rats.

Authors:  M Rebuelto; L Ambros; M Rubio
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

9.  Study of relationship between volume of distribution and body weight application to amikacin.

Authors:  L Rughoo; L Bourguignon; P Maire; M Ducher
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2014-03-06       Impact factor: 2.441

10.  The pharmacokinetics and toxicity of morning vs. evening tobramycin dosing for pulmonary exacerbations of cystic fibrosis: A randomised comparison.

Authors:  A P Prayle; K Jain; D J Touw; B C P Koch; A J Knox; A Watson; A R Smyth
Journal:  J Cyst Fibros       Date:  2015-08-15       Impact factor: 5.482

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.